GLP1R and Alzheimer disease: If these trials could demonstrate the efficacy of GLP-1 RAs (as preclinical and phase II studies seem to suggest) as a relevant treatment of AD, this would undoubtedly represent a breakthrough and an enormous hope, since their use is widespread and well known, in particular to diabetologists.